A Phase 3 interventional study of Meningococcal vaccine GSK134612 and Boostrix® in Infections, Meningococcal, sponsored by GlaxoSmithKline. Completed at 15 sites in 3 countries. Open to participants aged 11 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-06.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Meningococcal Infections by GlaxoSmithKline — none open to participants now, 1 under way, none of them phase 3. Meningococcal Infections · GlaxoSmithKline.
Among the 71 studies in Meningococcal Infections by GlaxoSmithKline, this one is the 33rd largest by enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2013, is one of 34 in phase 3, and was the 45th registered.
243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.
Browse Meningococcal Infections studies →None of the 71 studies in Meningococcal Infections by GlaxoSmithKline is open now. The open studies under Meningococcal Infections, anywhere →
Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 11 Years to 25 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 26 · Phase 3 34 · Phase 4 6
First in 2002; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 692 is above the median of 456 across 214 interventional studies indexed under Meningococcal Infections.
Median enrollment 613 across the 67 interventional studies, 119 across the 4 observational. Of the 70 that completed or were terminated, 60 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 71 studies in Meningococcal Infections by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the meningococcal conjugate vaccine (MenACWY-TT) co-administered with Boostrix® versus each of the two vaccines given separately in healthy adolescents and young adults.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects of non- may be enrolled in the study.
Female subjects of childbearing potential may be enrolled in the study, if the subject:
Exclusion Criteria:
Acute disease and/or fever at the time of enrolment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Nimenrix vaccine co-administered with one dose of Boostrix vaccine, at Month 0, administered by intramuscular injection into the deltoid muscle.
Biological: Meningococcal vaccine GSK134612 · Biological: Boostrix®
Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Nimenrix vaccine at Month 0 and one dose of Boostrix vaccine at Month 1. Both vaccines were administered by intramuscular injection into the deltoid muscle.
Biological: Meningococcal vaccine GSK134612 · Biological: Boostrix®
Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Boostrix vaccine at Month 0 and one dose of Nimenrix vaccine at Month 1. Both vaccines were administered by intramuscular injection into the deltoid muscle.
Biological: Meningococcal vaccine GSK134612 · Biological: Boostrix®
One dose administered intramuscularly (IM) in the deltoid muscle of the arm.
Also known as: MenACWY-TT, Nimenrix
One dose administered intramuscularly (IM) in the deltoid of the right arm (in Co-ad Group) and left arm (in TdapACWY and ACWYTdap Groups).
Also known as: Tdap
Anti-Meningitis Antibody Titers by Serum Bactericidal Assay Using Rabbit Complement (rSBA)
The analysis was performed for the serogroups -MenA, -MenC -MenW-135 and -MenY. Antibody titers tabulated as geometric mean titers (GMTs), were obtained by serum bactericidal assay using rabbit complement and expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL). The primary outcome results only refer to Nimenrix+Boostrix Group and Nimenrix Group.
Time frame: One month after Nimenrix vaccination (i.e. Month 1 for Nimenrix+Boostrix and Nimenrix Groups and Month 2 for Boostrix Group)
Number of Subjects With Anti-D and Anti-T Concentrations Above the Cut-off Value
The antibody concentrations were calculated as geometric mean concentrations (GMCs) and expressed as international units per milliliter (IU/mL). The reference cut-off value was an antibody concentration ≥ 1 IU/mL. The primary outcome results only refer to Nimenrix+Boostrix Group and Boostrix Group.
Time frame: One month after Boostrix vaccination (i.e. Month 1)
Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations
The antibody concentrations were tabulated as adjusted geometric mean concentrations (GMCs) and expressed as international units per millilitre (IU/mL). The primary outcome results only refer to Nimenrix+Boostrix Group and Boostrix Group
Time frame: One month after Boostrix vaccination (i.e. Month 1)
Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titres Above the Cut-off Values
The reference cut-off values of the assay were rSBA-Men antibody concentrations ≥ 1:128 and ≥ 1:8.
Time frame: Prior to (i.e. Month 0 for Nimenrix+Boostrix and Nimenrix Groups and Month 1 for Boostrix Group) and one month after Nimenrix vaccination (i.e. Month 1 for Nimenrix+Boostrix and Nimenrix Groups and Month 2 for Boostrix Group)
Vaccine Response for rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibodies
rSBA vaccine response for serogroups A, C, W-135 and Y was defined as: * For initially seronegative subjects (pre-vaccination titer below the cut-off of 1:8): number of subjects with rSBA antibody titers ≥ 1:32 one month after vaccination. * For initially seropositive subjects (pre-vaccination titer ≥ 1:8): number of subjects with rSBA antibody titers at least four times the pre-vaccination antibody titers, one month after vaccination.
Time frame: One month after Nimenrix vaccination (i.e. Month 1 for Nimenrix+Boostrix and Nimenrix Groups and Month 2 for Boostrix Group)
Anti-D Antibody Concentrations
The antibody concentrations were tabulated as geometric mean concentrations (GMCs) and expressed as international units per milliliter (IU/mL).
Time frame: Prior to (PRE i.e. Month 0 for Nimenrix + Boostrix Group and Boostrix Group and Month 1 for Nimenrix Group) and one month after Boostrix vaccination (POST i.e. Month 1 for Nimenrix + Boostrix Group and Boostrix Group and Month 2 for Nimenrix Group)
Anti-T Antibody Concentrations
The antibody concentrations were tabulated as geometric mean concentrations (GMCs) and expressed as international units per milliliter (IU/mL).
Time frame: Prior to (i.e. Month 0 for Nimenrix + Boostrix Group and Boostrix Group and Month 1 for Nimenrix Group), one month after Nimenrix vaccination and one month after Boostrix vaccination
Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations Above the Cut-off Value
The reference cut-off value of the assay was an antibody concentration ≥ 5.0 ELISA units per milliliter (EL.U/mL)
Time frame: Prior to (i.e. Month 0 for Nimenrix + Boostrix Group and Boostrix Group and Month 1 for Nimenrix Group) and one month after Boostrix vaccination (i.e. Month 1 for Nimenrix + Boostrix Group and Boostrix Group and Month 2 for Nimenrix Group)
Booster Responses for Anti-PT, Anti-FHA and Anti-PRN Concentrations
Booster response to the pertussis components is defined as: * For initially seronegative subjects, antibody concentration ≥ 4\*cut_off (IU/mL) at one month post-vaccination; * For initially seropositive subjects with pre-vaccination antibody concentration \< 4\*cut_off (IU/mL) : antibody concentration at one month post-vaccination ≥ 4 fold the pre-vaccination antibody concentration; * For initially seropositive subjects with pre-vaccination antibody concentration ≥ 4\*cut_off (IU/mL) : antibody concentration at one month post-vaccination ≥ 2 fold the pre-vaccination antibody concentration.
Time frame: One month after Boostrix vaccination (i.e. Month 1 for Nimenrix + Boostrix Group and Boostrix Group and Month 2 for Nimenrix Group)
Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. Results are presented across doses, after each vaccination (with Nimenrix, Boostrix, total).
Time frame: During the 4-day (Days 0-3) following each vaccination
Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination. Results are presented across doses.
Time frame: During the 4-day (Days 0-3) period following each vaccination
Number of Subjects With New Onset of Chronic Diseases (NOCDs)
NOCDs include autoimmune disorders, asthma, type I diabetes, allergies.
Time frame: Throughout the study (Month 0 up to Month 2)
Number of Subjects With Unsolicited Adverse Events AE(s)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: During the 31-day (Days 0-30) post-vaccination period
Number of Subjects With Serious Adverse Events SAE(s)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: Throughout the study (Month 0 up to Month 2)
| Milestone | Nimenrix+ Boostrix Group | Nimenrix Group | Boostrix Group |
|---|---|---|---|
| Started | 231 | 228 | 232 |
| Completed | 227 | 225 | 232 |
| Not completed | 4 | 3 | 0 |
| Withdrew: Lost to follow-up | 3 | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
The analysis was performed for the serogroups -MenA, -MenC -MenW-135 and -MenY. Antibody titers tabulated as geometric mean titers (GMTs), were obtained by serum bactericidal assay using rabbit complement and expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL). The primary outcome results only refer to Nimenrix+Boostrix Group and Nimenrix Group.
| EL.U/mL | Nimenrix + Boostrix Group | Nimenrix Group | Boostrix Group |
|---|---|---|---|
| rSBA-MenA | 3415.3 (2917.8 to 3997.6) | 2860.4 (2478.6 to 3300.9) | 1577.4 (1354.4 to 1837.1) |
| rSBA-MenC | 5092.5 (4268.7 to 6075.3) | 4597.6 (3703.1 to 5708.2) | 1912.6 (1593.9 to 2295.1) |
| rSBA-MenW-135 | 9608.5 (8522.5 to 10832.8) | 9052.8 (7510.3 to 10912.0) | 3164.6 (2534.0 to 3952.1) |
| rSBA-MenY | 7775.8 (6862.3 to 8811.0) | 6032.6 (5025.7 to 7241.2) | 4134.4 (3582.3 to 4771.5) |
The antibody concentrations were calculated as geometric mean concentrations (GMCs) and expressed as international units per milliliter (IU/mL). The reference cut-off value was an antibody concentration ≥ 1 IU/mL. The primary outcome results only refer to Nimenrix+Boostrix Group and Boostrix Group.
| Participants | Nimenrix + Boostrix Group | Boostrix Group |
|---|---|---|
| Anti-D | 200 | 203 |
| Anti-T | 224 | 223 |
The antibody concentrations were tabulated as adjusted geometric mean concentrations (GMCs) and expressed as international units per millilitre (IU/mL). The primary outcome results only refer to Nimenrix+Boostrix Group and Boostrix Group
| IU/mL | Nimenrix + Boostrix Group | Boostrix Group |
|---|---|---|
| Anti-PT | 53.6 (47.2 to 60.8) | 68.0 (59.9 to 77.3) |
| Anti-FHA | 316.9 (288.0 to 348.6) | 545.0 (493.2 to 602.4) |
| Anti-PRN | 348.3 (293.8 to 412.9) | 499.0 (419.4 to 593.6) |
The reference cut-off values of the assay were rSBA-Men antibody concentrations ≥ 1:128 and ≥ 1:8.
| Participants | Nimenrix + Boostrix Group | Nimenrix Group | Boostrix Group |
|---|---|---|---|
| rSBA-MenA ≥ 1:128 | 48 | 46 | 33 |
| rSBA-MenC ≥ 1:128 | 224 | 220 | 220 |
| rSBA-MenW-135 ≥ 1:128 | 13 | 33 | 30 |
| rSBA-MenY ≥ 1:128 | 225 | 218 | 220 |
| rSBA-MenA ≥ 1:8 | 31 | 29 | 23 |
| rSBA-MenC ≥ 1:8 | 226 | 220 | 216 |
| rSBA-MenW-135 ≥ 1:8 | 80 | 56 | 70 |
| rSBA-MenY ≥ 1:8 | 226 | 219 | 222 |
rSBA vaccine response for serogroups A, C, W-135 and Y was defined as: * For initially seronegative subjects (pre-vaccination titer below the cut-off of 1:8): number of subjects with rSBA antibody titers ≥ 1:32 one month after vaccination. * For initially seropositive subjects (pre-vaccination titer ≥ 1:8): number of subjects with rSBA antibody titers at least four times the pre-vaccination antibody titers, one month after vaccination.
| Participants | Nimenrix + Boostrix Group | Nimenrix Group | Boostrix Group |
|---|---|---|---|
| rSBA-MenA | 217 | 207 | 214 |
| rSBA-MenC | 225 | 210 | 215 |
| rSBA-MenW-135 | 225 | 216 | 211 |
| rSBA-MenY | 220 | 214 | 212 |
The antibody concentrations were tabulated as geometric mean concentrations (GMCs) and expressed as international units per milliliter (IU/mL).
| IU/mL | Nimenrix + Boostrix Group | Nimenrix Group | Boostrix Group |
|---|---|---|---|
| Anti-D, PRE | 0.3 (0.3 to 0.4) | 0.3 (0.3 to 0.4) | 0.3 (0.3 to 0.4) |
| Anti-D, POST | 4.0 (3.4 to 4.6) | 4.6 (3.9 to 5.4) | 4.7 (4.0 to 5.4) |
The antibody concentrations were tabulated as geometric mean concentrations (GMCs) and expressed as international units per milliliter (IU/mL).
| IU/mL | Nimenrix + Boostrix Group | Nimenrix Group | Boostrix Group |
|---|---|---|---|
| Anti-T, pre-vaccination | 0.6 (0.5 to 0.8) | 0.6 (0.5 to 0.7) | 0.7 (0.5 to 0.8) |
| Anti-T, Month 1 | 23.5 (20.8 to 26.5) | 18.5 (16.0 to 21.3) | 13.5 (12.3 to 14.8) |
| Anti-T, Month 2 | — | 13.0 (11.7 to 14.5) | 16.3 (14.6 to 18.2) |
The reference cut-off value of the assay was an antibody concentration ≥ 5.0 ELISA units per milliliter (EL.U/mL)
| Participants | Nimenri+ Boostrix Group | Nimenrix Group | Boostrix Group |
|---|---|---|---|
| Anti-PT, PRE | 162 | 156 | 153 |
| Anti-PT, Month 1/Month 2 | 221 | 220 | 223 |
| Anti-FHA, PRE | 222 | 221 | 220 |
| Anti-FHA, Month 1/Month 2 | 225 | 220 | 223 |
| Anti-PRN, PRE | 200 | 200 | 207 |
| Anti-PRN, Month 1/Month 2 | 223 | 218 | 221 |
Booster response to the pertussis components is defined as: * For initially seronegative subjects, antibody concentration ≥ 4\*cut_off (IU/mL) at one month post-vaccination; * For initially seropositive subjects with pre-vaccination antibody concentration \< 4\*cut_off (IU/mL) : antibody concentration at one month post-vaccination ≥ 4 fold the pre-vaccination antibody concentration; * For initially seropositive subjects with pre-vaccination antibody concentration ≥ 4\*cut_off (IU/mL) : antibody concentration at one month post-vaccination ≥ 2 fold the pre-vaccination antibody concentration.
| Participants | Nimenrix + Boostrix Group | Nimenrix Group | Boostrix Group |
|---|---|---|---|
| Anti-PT antibody (assay cut-off=2.693 IU/mL) | 201 | 188 | 201 |
| Anti-FHA antibody (assay cut-off=2.046 IU/mL) | 208 | 210 | 213 |
| Anti-PRN antibody (assay cut-off=2.187 IU/mL) | 209 | 198 | 207 |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. Results are presented across doses, after each vaccination (with Nimenrix, Boostrix, total).
| Participants | Nimenrix + Boostrix Group | Nimenrix Group | Boostrix Group |
|---|---|---|---|
| Any Pain, Total | 176 | 148 | 167 |
| Grade 3 Pain, Total | 15 | 19 | 8 |
| Any Redness, Total | 81 | 75 | 76 |
| Grade 3 Redness, Total | 4 | 10 | 6 |
| Any Swelling, Total | 71 | 71 | 68 |
| Grade 3 Swelling, Total | 5 | 9 | 7 |
| Any Pain, post-Nimenrix | 155 | 121 | 156 |
| Grade 3 Pain, post-Nimenrix | 13 | 12 | 8 |
| Any Redness, post-Nimenrix | 64 | 56 | 65 |
| Grade 3 Redness, post-Nimenrix | 3 | 5 | 5 |
| Any Swelling, post-Nimenrix | 57 | 51 | 54 |
| Grade 3 Swelling, post-Nimenrix | 3 | 4 | 7 |
| Any Pain, post-Boostrix | 121 | 101 | 92 |
| Grade 3 Pain, post-Boostrix | 7 | 8 | 0 |
| Any Redness, post-Boostrix | 61 | 54 | 39 |
| Grade 3 Redness, post-Boostrix | 1 | 6 | 4 |
| Any Swelling, post-Boostrix | 48 | 47 | 33 |
| Grade 3 Swelling, post-Boostrix | 3 | 5 | 1 |
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination. Results are presented across doses.
| Participants | Nimenrix + Boostrix Group | Nimenrix Group | Boostrix Group |
|---|---|---|---|
| Any Fatigue | 75 | 77 | 81 |
| Grade 3 Fatigue | 2 | 5 | 4 |
| Related Fatigue | 70 | 67 | 70 |
| Any Gastrointestinal symptoms | 23 | 31 | 25 |
| Grade 3 Gastrointestinal symptoms | 2 | 2 | 1 |
| Related Gastrointestinal symptoms | 20 | 25 | 18 |
| Any Headache | 51 | 76 | 65 |
| Grade 3 Headache | 2 | 5 | 2 |
| Related Headache | 49 | 67 | 53 |
| Any Temperature | 14 | 17 | 11 |
| Grade 3 Temperature | 0 | 0 | 0 |
| Related Temperature | 10 | 15 | 9 |
NOCDs include autoimmune disorders, asthma, type I diabetes, allergies.
| Participants | Nimenrix + Boostrix Group | Nimenrix Group | Boostrix Group |
|---|---|---|---|
| Number of Subjects With New Onset of Chronic Diseases (NOCDs) | 1 | 5 | 3 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
| Participants | Nimenrix + Boostrix Group | Nimenrix Group | Boostrix Group |
|---|---|---|---|
| Number of Subjects With Unsolicited Adverse Events AE(s) | 36 | 44 | 58 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | Nimenrix + Boostrix Group | Nimenrix Group | Boostrix Group |
|---|---|---|---|
| Number of Subjects With Serious Adverse Events SAE(s) | 0 | 0 | 3 |
Collected over Solicited local and general symptoms: during the 4-day (Days 0-3) period following each vaccination; Unsolicited AEs: during the 31-day (Days 0-30) post-vaccination period; SAEs: throughout the study (Month 0 - Month 2).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nimenrix+ Boostrix Group | 0/231 (0%) | 0/231 (0%) | 190/231 (82.3%) |
| Nimenrix Group | 0/228 (0%) | 0/228 (0%) | 166/228 (72.8%) |
| Boostrix Group | 0/232 (0%) | 3/232 (1.3%) | 180/232 (77.6%) |
| Event | Nimenrix+ Boostrix Group | Nimenrix Group | Boostrix Group |
|---|---|---|---|
| GastroenteritisInfections and infestations | 0/231 | 0/228 | 1/232 |
| Orthostatic intoleranceNervous system disorders | 0/231 | 0/228 | 1/232 |
| DepressionPsychiatric disorders | 0/231 | 0/228 | 1/232 |
| Event | Nimenrix+ Boostrix Group | Nimenrix Group | Boostrix Group |
|---|---|---|---|
| PainGeneral disorders | 176/231 | 148/228 | 167/232 |
| ErythemaSkin and subcutaneous tissue disorders | 81/231 | 75/228 | 76/232 |
| FatigueGeneral disorders | 75/231 | 77/228 | 81/232 |
| HeadacheNervous system disorders | 54/231 | 78/228 | 67/232 |
| SwellingGeneral disorders | 71/231 | 71/228 | 68/232 |
| Gastrointestinal disorderGastrointestinal disorders | 23/231 | 31/228 | 25/232 |
| PyrexiaGeneral disorders | 15/231 | 17/228 | 11/232 |
| NasopharyngitisInfections and infestations | 6/231 | 8/228 | 15/232 |
| Age, Continuous(Years) | Nimenrix+ Boostrix Group | Nimenrix Group | Boostrix Group | Total |
|---|---|---|---|---|
| Mean | 18.1 ± 4.2 | 18.2 ± 4.5 | 18.3 ± 4.4 | 18.2 ± 4.4 |
| Sex: Female, Male(Participants) | Nimenrix+ Boostrix Group | Nimenrix Group | Boostrix Group | Total |
|---|---|---|---|---|
| Female | 128 | 126 | 146 | 400 |
| Male | 103 | 102 | 86 | 291 |
| Race/Ethnicity, Customized(Participants) | Nimenrix+ Boostrix Group | Nimenrix Group | Boostrix Group | Total |
|---|---|---|---|---|
| Ethnicity — Asian - East Asian Heritage | 111 | 109 | 111 | 331 |
| Ethnicity — Asian - South East Asian Heritage | 0 | 0 | 1 | 1 |
| Ethnicity — White - Caucasian / European Heritage | 60 | 60 | 61 | 181 |
| Ethnicity — Other | 60 | 59 | 59 | 178 |
Ran from Jan 2013 to primary completion in Jan 2014, 12 months.
Results were first posted in Sep 2017, 3 years 7 months after primary completion. A results delay was requested in May 2014.
Of 46 industry-sponsored phase 3 interventional studies under Meningococcal Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 12 months is below that.
Counting every sponsor, half of 46 studies reached it within 15 months; a quarter within 8 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Boostrix